Newsroom | 36431 results

Sorted by: Latest
Medical Devices
-

Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine

CHICAGO--(BUSINESS WIRE)--Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology.i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions. “PET/CT has revolutionized the way we understand and treat disease by allowing us to visu...
-

PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine

GOLDEN, Colo.--(BUSINESS WIRE)--Agreement with Immuno Cure adds to PharmaJet's portfolio of global development partnerships with innovative oncology & infectious disease developers....
-

Surgimate Appoints Jessica Cook as Chief Revenue Officer

NEW YORK--(BUSINESS WIRE)--Surgimate, a leading provider of surgical coordination and scheduling software in the U.S., today announced the appointment of Jessica Cook to the newly created position of Chief Revenue Officer. As CRO, Cook will oversee all sales and marketing efforts across Surgimate’s business lines, including surgical scheduling, medical device coordination and patient access. She will also work closely with Surgimate CEO Kraig Brown to implement strategies that drive growth and...
-

Cube Click, Inc. Secures FDA Approval for SMILE Dx—A Game-Changer in Dental AI Diagnostics

NEW YORK--(BUSINESS WIRE)--FDA APPROVES SMILE Dx....
-

Resumen: Brenus Pharma e InSphero han desarrollado esferoides tumorales en 3D que imitan las condiciones in vivo del cáncer colorrectal humano y confirman la eficacia de STC-1010

LISBOA, Portugal--(BUSINESS WIRE)--Brenus Pharma, empresa biotecnológica francesa dedicada al desarrollo de inmunoterapias innovadores de nueva generación, e InSphero, líder suizo en tecnologías de ensayos basadas en células 3D, presentaron datos prometedores en el congreso anual de la Asociación Europea para la Investigación del Cáncer 2025. Estos datos corroboran el uso de esferoides tumorales 3D para evaluar la eficacia de STC-1010, el principal candidato de Brenus contra el cáncer colorrect...
-

Brenus Pharma et InSphero ont mis au point des sphéroïdes tumorales 3D imitant les conditions in vivo de cancer colorectal humain et confirmant l'efficacité du STC-1010

LISBONNE, Portugal--(BUSINESS WIRE)--Brenus Pharma, la biotech française développant des immunothérapies de nouvelle génération, et InSphero, le chef de file suisse des technologies d'analyse 3D à base de cellules, ont présenté des données prometteuses lors du congrès annuel 2025 de l'Association européenne pour la recherche sur le cancer. Ces données confirment l’utilisation de sphéroïdes tumoraux 3D pour le test de puissance du STC-1010, candidat principal de Brenus dans le traitement du canc...
-

Brenus Pharma und InSphero haben 3D-Tumorsphäroide entwickelt, die in vivo menschliche Darmkrebserkrankungen nachahmen und die Wirksamkeit von STC-1010 bestätigen

LISSABON, Portugal--(BUSINESS WIRE)--Brenus Pharma, ein französisches Biotechunternehmen, das First-in-Class-Immuntherapien der nächsten Generation entwickelt, und InSphero, ein Schweizer Marktführer bei 3D-Zell-Assay-Technologien, haben auf dem Jahreskongress 2025 der European Association for Cancer Research vielversprechende Daten präsentiert. Diese Daten bestätigen den Nutzen von 3D-Tumorsphäroiden bei der Wirksamkeitsprüfung von STC-1010, dem führenden Wirkstoffkandidaten von Brenus für Dar...
-

Riassunto: Brenus Pharma e InSphero hanno sviluppato sferoidi tumorali tridimensionali che imitano in vivo le condizioni del tumore del colon-retto nell'uomo e confermano l'efficacia di STC-1010

LISBONA, Portogallo--(BUSINESS WIRE)--Brenus Pharma, azienda biotecnologica francese che sviluppa immunoterapie di nuova generazione prime nel settore, e InSphero, un leader svizzero nelle tecnologie di saggi a base cellulare tridimensionali, ha presentato dati promettenti al congresso annuale 2025 della European Association for Cancer Research. Questi dati confermano l'uso di sferoidi tumorali tridimensionali per testare l'efficacia di STC-1010, il principale candidato farmaco per il tumore de...
-

ZAP Surgical anuncia los primeros tratamientos con la plataforma ZAP-X Gyroscopic Radiosurgery en Latinoamérica

SAN CARLOS, California--(BUSINESS WIRE)--ZAP Surgical Systems, Inc. líder mundial en cirugía cerebral robótica no invasiva, anunció hoy los primeros tratamientos de pacientes utilizando su plataforma ZAP-X® Gyroscopic Radiosurgery® en Latinoamérica. Ubicada en Neuland, Boquerón, Paraguay, Radioterapia Concordia (www.saludconcordia.com) ha comenzado oficialmente su uso clínico, marcando un hito importante en la descentralización de la atención vanguardista para tumores cerebrales en toda la regi...
-

ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery Patient Treatments in Latin America

SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia (www.saludconcordia.com) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region. In its first day of operation, f...